Nichi-Iko Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Nichi-Iko Pharmaceutical Co., Ltd. carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 190.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | 190.49B |
Share Statistics
Nichi-Iko Pharmaceutical Co., Ltd. currently has 1.00 shares outstanding.
| Shares Outstanding | 1.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is -NaN, and the price-to-book ratio stands at -NaN.
| PE Ratio | N/A |
| PS Ratio | -NaN |
| PB Ratio | -NaN |
| P/TBV Ratio | -NaN |
| P/FCF Ratio | -NaN |
| P/OCF Ratio | -NaN |
Enterprise Valuation
| EV / Sales | 1.04 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Nichi-Iko Pharmaceutical Co., Ltd. maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -389.89, indicating conservative leverage, while an interest coverage ratio of -33.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.89 |
| Quick Ratio | 0.07 |
| Debt / Equity | -389.89 |
| Debt / EBITDA | -1.22 |
| Interest Coverage | -33.20 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -53.91 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.20 |
Taxes
| Income Tax | -3.75B |
| Effective Tax Rate | N/A |
Stock Price Statistics
Nichi-Iko Pharmaceutical Co., Ltd.'s stock has gained approximately 0% over the past 52 weeks. The 50-day moving average sits at 0.36, while the 200-day moving average is 0.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Nichi-Iko Pharmaceutical Co., Ltd. generated 182.88B in revenue and converted that into -160.44B in net income, yielding earnings per share of -161.24B. EBITDA reached -165.95B, while operating income came in at -165.95B.
| Revenue | 182.88B |
| Gross Profit | -12.81B |
| Operating Income | -165.95B |
| Pretax Income | -164.99B |
| Net Income | -160.44B |
| EBITDA | -165.95B |
| EBIT | -165.95B |
| Earnings Per Share (EPS) | -161.24B |
Balance Sheet
Nichi-Iko Pharmaceutical Co., Ltd. holds 12.50B in cash and equivalents against 203.14B in total debt, resulting in a net debt position of 190.80B. Total book value stands at -101.19B, with working capital of -21.60B providing operational flexibility.
| Cash & Cash Equivalents | 12.50B |
| Total Debt | 203.14B |
| Net Debt | 190.80B |
| Equity (Book Value) | -101.19B |
| Book Value Per Share | -101.19B |
| Working Capital | -21.60B |
Cash Flow
Nichi-Iko Pharmaceutical Co., Ltd. produced -35.05B in operating cash flow over the past twelve months. After subtracting -8.46B in capital expenditures, free cash flow totaled -43.52B - equivalent to -43.52B per share.
| Operating Cash Flow | -35.05B |
| Capital Expenditures | -8.46B |
| Free Cash Flow | -43.52B |
| FCF Per Share | -43.52B |
Margins
Nichi-Iko Pharmaceutical Co., Ltd. operates with a gross margin of -7.01, reflecting its pricing power and cost economics. The operating margin of -90.74 and net profit margin of -87.73 provide insight into operational efficiency.
| Gross Margin | -7.01 |
| Operating Margin | -90.74 |
| Pretax Margin | -90.22 |
| Profit Margin | -87.73 |
| EBITDA Margin | -90.74 |
Dividends & Yields
The company's payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 2.00M |
| Dividend Yield | N/A |
| Payout Ratio | 0.00 |
| Shareholder Yield | -25.64B |
| FCF Yield | -20.07B |
Scores
Nichi-Iko Pharmaceutical Co., Ltd. posts an Altman Z-Score of -2.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.65 |